
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte Inc. demonstrated a robust performance, with genomic test volume increasing by 25% to 39,107, driven largely by a remarkable 45% growth in Decipher urology tests, reflecting strong market demand. The company also achieved a significant increase in adjusted EBITDA margin, up 690 basis points year-over-year, highlighting improved operational efficiency and profitability. Furthermore, the impressive growth in revenue from Bethesda V and VI nodules following the July 2024 LCD for Afirma, along with management's optimistic guidance for adjusted EBITDA margins in 2025, underscores a positive outlook for the company moving forward.
Bears say
Veracyte Inc. faces a negative outlook primarily due to a slowdown in revenue growth, which declined from 29% in 3Q24 to 21% in 4Q24, driven by underperformance in key products like Afirma and Decipher tests. Additionally, testing revenue per test has decreased slightly, indicating potential pricing pressure, while a bear case scenario anticipates continued challenges with sustained revenue growth of only 10-15%. The company also faces significant risks including slower adoption of new diagnostic tests, reimbursement issues, and potential setbacks related to its Percepta Nasal Swab test, all of which could adversely impact its financial stability moving forward.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares